Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders Growth (1y) (2014 - 2020)
Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders Growth (1y) (2014 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Galmed Pharmaceuticals |
2.48 Mn |
-1.63 Mn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
49.54% |
| Dec 31, 2019 |
123.58% |
| Sep 30, 2019 |
457.97% |
| Mar 31, 2019 |
75.65% |
| Dec 31, 2018 |
1.70% |
| Sep 30, 2018 |
-71.12% |
| Jun 30, 2018 |
-0.26% |
| Mar 31, 2018 |
-22.40% |
| Dec 31, 2017 |
-24.49% |
| Sep 30, 2017 |
-22.67% |
| Jun 30, 2017 |
-37.53% |
| Mar 31, 2017 |
-20.27% |
| Dec 31, 2016 |
50.58% |
| Sep 30, 2016 |
39.31% |
| Jun 30, 2016 |
83.05% |
| Mar 31, 2016 |
65.89% |
| Dec 30, 2015 |
62.03% |
| Sep 30, 2015 |
-18.08% |
| Jun 30, 2015 |
33.07% |
| Mar 31, 2015 |
-91.45% |
